The Experts below are selected from a list of 24 Experts worldwide ranked by ideXlab platform
Samir Gupta - One of the best experts on this subject based on the ideXlab platform.
-
Pancreas Cancer Incidence and Pancreas Cancer-Associated Mortality Are Low in National Cohort of 7211 Pancreas Cyst Patients.
Digestive diseases and sciences, 2021Co-Authors: Gobind S Anand, Fady Youssef, Lin Liu, Ranier Bustamante, Ashley Earles, Santhi Swaroop Vege, Thomas Savides, Syed Abbas Fehmi, Wilson T Kwong, Samir GuptaAbstract:Pancreatic cancer incidence and mortality among patients with Pancreas Cysts are unclear. The aims of this study are to evaluate incidence of pancreatic cancer and cause-specific mortality among patients with pancreatic Cysts using a large national cohort over a long follow-up period. We conducted a retrospective cohort study of US Veterans diagnosed with a pancreatic Cyst 1999-2013, based on International Classification of Diseases, 9th edition (ICD9) coding within national Department of Veterans Affairs (VA) data. Pancreatic cancer incidence was ascertained using VA cancer registry data, ICD-9 codes, and the National Death Index, a national centralized database of death records, including cause-specific mortality. Among 7211 Veterans with pancreatic Cysts contributing 31,501 person-years of follow-up (median follow-up 4.4 years), 79 (1.1%) developed pancreatic cancer. A total of 1982 patients (27.5%) died during the study follow-up period. Sixty-three patients (3.2% of deaths; 0.9% of Pancreas Cyst cohort) died from pancreatic cancer, but the leading causes of death in the cohort were non-pancreatic cancer (n = 498, 25% of deaths) and cardiovascular disease (n = 398, 20% of deaths). Pancreas cancer incidence and pancreatic cancer-associated mortality are very low in a large national cohort of VA pancreatic Cyst patients with long-term follow-up. Most deaths were from non-Pancreas cancers and cardiovascular causes, and only a minority (3.2%) were attributable to Pancreas cancer. Given death from Pancreas cancer is rare, future research should focus on identifying criteria for selecting individuals at high risk for death from pancreatic cancer for pancreatic Cyst surveillance.
William R Brugge - One of the best experts on this subject based on the ideXlab platform.
-
ethanol lavage of pancreatic Cystic lesions initial pilot study
Gastrointestinal Endoscopy, 2005Co-Authors: Ian S Gan, Christopher C Thompson, Gregory Y Lauwers, Brenna C Bounds, William R BruggeAbstract:Background Ethanol lavage has been used to successfully and safely ablate Cystic lesions of the liver, the kidneys, and the thyroid. Methods Asymptomatic patients who undergo EUS examination for a pancreatic Cystic lesion were eligible. Patients underwent complete examination with a linear-array echoendoscope, and Cyst characteristics were documented. After evacuation of the Cyst with needle aspiration, the Cyst cavity was lavaged with ethanol for 3 to 5 minutes. The concentration (5%-80%) of ethanol was gradually increased over the course of the study. Patients were monitored for complications during 2 hours after the procedure, and further follow-up was obtained at 72 hours and 1 year after lavage. Observations Twenty-five patients were enrolled, 80% were women, and the mean age of all patients was 64.5 years. Cysts had a mean diameter of 19.4 mm and were equally located in the head, the body, and the tail of the Pancreas. Cyst-fluid characteristics included high viscosity in 13 (52%) and a mean carcinoembryonic antigen and amylase of 5916 ng/mL and 11,506 U/L, respectively. None of the patients reported any symptoms in short- and long-term follow-up. Of the 23/25 patients with complete follow-up, 8 patients (35%) had complete resolution of their Cysts on follow-up imaging. Five patients underwent resection, and histologic evidence of epithelial ablation was seen. Conclusions Ethanol lavage of pancreatic Cystic lesions is safe and feasible. A subset of patients undergoing ethanol lavage appears to have long-term resolution on follow-up imaging. Further prospective studies are required to determine if ethanol lavage is an effective treatment for pancreatic Cystic lesions.
Gobind S Anand - One of the best experts on this subject based on the ideXlab platform.
-
Pancreas Cancer Incidence and Pancreas Cancer-Associated Mortality Are Low in National Cohort of 7211 Pancreas Cyst Patients.
Digestive diseases and sciences, 2021Co-Authors: Gobind S Anand, Fady Youssef, Lin Liu, Ranier Bustamante, Ashley Earles, Santhi Swaroop Vege, Thomas Savides, Syed Abbas Fehmi, Wilson T Kwong, Samir GuptaAbstract:Pancreatic cancer incidence and mortality among patients with Pancreas Cysts are unclear. The aims of this study are to evaluate incidence of pancreatic cancer and cause-specific mortality among patients with pancreatic Cysts using a large national cohort over a long follow-up period. We conducted a retrospective cohort study of US Veterans diagnosed with a pancreatic Cyst 1999-2013, based on International Classification of Diseases, 9th edition (ICD9) coding within national Department of Veterans Affairs (VA) data. Pancreatic cancer incidence was ascertained using VA cancer registry data, ICD-9 codes, and the National Death Index, a national centralized database of death records, including cause-specific mortality. Among 7211 Veterans with pancreatic Cysts contributing 31,501 person-years of follow-up (median follow-up 4.4 years), 79 (1.1%) developed pancreatic cancer. A total of 1982 patients (27.5%) died during the study follow-up period. Sixty-three patients (3.2% of deaths; 0.9% of Pancreas Cyst cohort) died from pancreatic cancer, but the leading causes of death in the cohort were non-pancreatic cancer (n = 498, 25% of deaths) and cardiovascular disease (n = 398, 20% of deaths). Pancreas cancer incidence and pancreatic cancer-associated mortality are very low in a large national cohort of VA pancreatic Cyst patients with long-term follow-up. Most deaths were from non-Pancreas cancers and cardiovascular causes, and only a minority (3.2%) were attributable to Pancreas cancer. Given death from Pancreas cancer is rare, future research should focus on identifying criteria for selecting individuals at high risk for death from pancreatic cancer for pancreatic Cyst surveillance.
Syed Abbas Fehmi - One of the best experts on this subject based on the ideXlab platform.
-
Pancreas Cancer Incidence and Pancreas Cancer-Associated Mortality Are Low in National Cohort of 7211 Pancreas Cyst Patients.
Digestive diseases and sciences, 2021Co-Authors: Gobind S Anand, Fady Youssef, Lin Liu, Ranier Bustamante, Ashley Earles, Santhi Swaroop Vege, Thomas Savides, Syed Abbas Fehmi, Wilson T Kwong, Samir GuptaAbstract:Pancreatic cancer incidence and mortality among patients with Pancreas Cysts are unclear. The aims of this study are to evaluate incidence of pancreatic cancer and cause-specific mortality among patients with pancreatic Cysts using a large national cohort over a long follow-up period. We conducted a retrospective cohort study of US Veterans diagnosed with a pancreatic Cyst 1999-2013, based on International Classification of Diseases, 9th edition (ICD9) coding within national Department of Veterans Affairs (VA) data. Pancreatic cancer incidence was ascertained using VA cancer registry data, ICD-9 codes, and the National Death Index, a national centralized database of death records, including cause-specific mortality. Among 7211 Veterans with pancreatic Cysts contributing 31,501 person-years of follow-up (median follow-up 4.4 years), 79 (1.1%) developed pancreatic cancer. A total of 1982 patients (27.5%) died during the study follow-up period. Sixty-three patients (3.2% of deaths; 0.9% of Pancreas Cyst cohort) died from pancreatic cancer, but the leading causes of death in the cohort were non-pancreatic cancer (n = 498, 25% of deaths) and cardiovascular disease (n = 398, 20% of deaths). Pancreas cancer incidence and pancreatic cancer-associated mortality are very low in a large national cohort of VA pancreatic Cyst patients with long-term follow-up. Most deaths were from non-Pancreas cancers and cardiovascular causes, and only a minority (3.2%) were attributable to Pancreas cancer. Given death from Pancreas cancer is rare, future research should focus on identifying criteria for selecting individuals at high risk for death from pancreatic cancer for pancreatic Cyst surveillance.
Wilson T Kwong - One of the best experts on this subject based on the ideXlab platform.
-
Pancreas Cancer Incidence and Pancreas Cancer-Associated Mortality Are Low in National Cohort of 7211 Pancreas Cyst Patients.
Digestive diseases and sciences, 2021Co-Authors: Gobind S Anand, Fady Youssef, Lin Liu, Ranier Bustamante, Ashley Earles, Santhi Swaroop Vege, Thomas Savides, Syed Abbas Fehmi, Wilson T Kwong, Samir GuptaAbstract:Pancreatic cancer incidence and mortality among patients with Pancreas Cysts are unclear. The aims of this study are to evaluate incidence of pancreatic cancer and cause-specific mortality among patients with pancreatic Cysts using a large national cohort over a long follow-up period. We conducted a retrospective cohort study of US Veterans diagnosed with a pancreatic Cyst 1999-2013, based on International Classification of Diseases, 9th edition (ICD9) coding within national Department of Veterans Affairs (VA) data. Pancreatic cancer incidence was ascertained using VA cancer registry data, ICD-9 codes, and the National Death Index, a national centralized database of death records, including cause-specific mortality. Among 7211 Veterans with pancreatic Cysts contributing 31,501 person-years of follow-up (median follow-up 4.4 years), 79 (1.1%) developed pancreatic cancer. A total of 1982 patients (27.5%) died during the study follow-up period. Sixty-three patients (3.2% of deaths; 0.9% of Pancreas Cyst cohort) died from pancreatic cancer, but the leading causes of death in the cohort were non-pancreatic cancer (n = 498, 25% of deaths) and cardiovascular disease (n = 398, 20% of deaths). Pancreas cancer incidence and pancreatic cancer-associated mortality are very low in a large national cohort of VA pancreatic Cyst patients with long-term follow-up. Most deaths were from non-Pancreas cancers and cardiovascular causes, and only a minority (3.2%) were attributable to Pancreas cancer. Given death from Pancreas cancer is rare, future research should focus on identifying criteria for selecting individuals at high risk for death from pancreatic cancer for pancreatic Cyst surveillance.
